172 related articles for article (PubMed ID: 2949833)
21. Cyclophosphamide-induced immunologically mediated regression of a cyclophosphamide-resistant murine tumor: a consequence of eliminating precursor L3T4+ suppressor T-cells.
Awwad M; North RJ
Cancer Res; 1989 Apr; 49(7):1649-54. PubMed ID: 2522344
[TBL] [Abstract][Full Text] [Related]
22. Changes in tumor-associated NK 1.1+ large granular lymphocyte precursors after cyclophosphamide injection: in vitro characterization and potential therapeutic application.
Krupke DM; Fuller J; Aslakson C; Evans R
Nat Immun; 1994; 13(5):246-57. PubMed ID: 7833624
[TBL] [Abstract][Full Text] [Related]
23. CD4-positive T lymphocytes are required for the generation of the primary but not the secondary CD8-positive cytolytic T lymphocyte response to herpes simplex virus in C57BL/6 mice.
Jennings SR; Bonneau RH; Smith PM; Wolcott RM; Chervenak R
Cell Immunol; 1991 Mar; 133(1):234-52. PubMed ID: 1671342
[TBL] [Abstract][Full Text] [Related]
24. Cyclophosphamide-induced appearance of immunopotentiating T-cells in the spleens of mice bearing a large MOPC-315 tumor.
Ye QW; Mokyr MB
Cancer Res; 1984 Sep; 44(9):3873-9. PubMed ID: 6611201
[TBL] [Abstract][Full Text] [Related]
25. Melphalan-induced appearance of potent antitumor immune reactivity in tumor bearer lymphocytes co-expressing the Lyt 2 and the L3T4 antigens.
Takesue BY; Bartik MM; Mokyr MB
Int J Immunopharmacol; 1987; 9(6):705-17. PubMed ID: 2891627
[TBL] [Abstract][Full Text] [Related]
26. The origin of cytotoxic T lymphocyte precursors (CTL-P): MHC-restricted and alloreactive CTL-P in the spleen during regeneration after a sublethal dose of cyclophosphamide (Cy).
Sihvola M; Hurme M
J Immunol; 1983 Mar; 130(3):1077-83. PubMed ID: 6600471
[TBL] [Abstract][Full Text] [Related]
27. Chemo-immunotherapy of murine solid tumors: enhanced therapeutic effects by interleukin-2 combined with interferon alpha and the role of specific T cells.
Kedar E; Rutkowski Y; Leshem B
Cancer Immunol Immunother; 1992; 35(1):63-8. PubMed ID: 1611625
[TBL] [Abstract][Full Text] [Related]
28. Reconstitution of cytolytic alloreactivity with N-[4-[(4-fluorophenyl) sulfonyl]phenyl]acetamide (CL 259,763) in animals immunocompromised by cyclophosphamide.
Wang BS; Lumanglas AL; James JP; Kelley KA; Silva J; Ruszala-Mallon V; Lin YI; Durr FE
Int J Immunopharmacol; 1989; 11(5):479-86. PubMed ID: 2530180
[TBL] [Abstract][Full Text] [Related]
29. A role of L3T4+ antigen in the Con A response of regenerating splenic L3T4+ T cells after Cy treatment.
Ikezawa Z; Sato M; Aoki I
Immunology; 1987 Mar; 60(3):375-82. PubMed ID: 3106196
[TBL] [Abstract][Full Text] [Related]
30. "In vivo" activated splenic T cells are refractory to interleukin 2 growth "in vitro".
Bandeira A; Larsson EL; Forni L; Pereira P; Coutinho A
Eur J Immunol; 1987 Jul; 17(7):901-8. PubMed ID: 3111860
[TBL] [Abstract][Full Text] [Related]
31. Tumor-specific chemoimmunotherapy of murine fibrosarcoma using tumor-specific transplantation antigen, cyclophosphamide, and interleukin-2.
Naito K; Nomi S; Komichi H; Ueda Y; Yamagishi H; Oka T; Pellis NR; Kahan BD
Cancer Detect Prev; 1992; 16(5-6):321-7. PubMed ID: 1361881
[TBL] [Abstract][Full Text] [Related]
32. Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor beta 1.
Inge TH; Hoover SK; Susskind BM; Barrett SK; Bear HD
Cancer Res; 1992 Mar; 52(6):1386-92. PubMed ID: 1531782
[TBL] [Abstract][Full Text] [Related]
33. Effects of cyclophosphamide treatment on the in vitro activity of mouse lymphoid cells after nonspecific and specific stimulation.
Snippe H; Davidse RP; Belder M; Willers JM
Int Arch Allergy Appl Immunol; 1976; 50(5):536-47. PubMed ID: 1083834
[TBL] [Abstract][Full Text] [Related]
34. Inhibition of cytotoxic T-cell clonal expansion by cyclophosphamide and the recovery of cytotoxic T-lymphocyte precursors by supernatants from mixed-lymphocyte cultures.
Merluzzi VJ; Walker MM; Faanes RB
Cancer Res; 1981 Mar; 41(3):850-3. PubMed ID: 6450638
[TBL] [Abstract][Full Text] [Related]
35. Cyclophosphamide-mediated enhancement of antitumor immune potential of immunosuppressed spleen cells from mice bearing a large MOPC-315 tumor.
Mokyr MB; Colvin M; Dray S
Int J Immunopharmacol; 1985; 7(1):111-22. PubMed ID: 3922904
[TBL] [Abstract][Full Text] [Related]
36. Protective immunity in murine histoplasmosis: functional comparison of adoptively transferred T-cell clones and splenic T cells.
Deepe GS
Infect Immun; 1988 Sep; 56(9):2350-5. PubMed ID: 3261717
[TBL] [Abstract][Full Text] [Related]
37. Paclitaxel vs cyclophosphamide in peripheral blood stem cell mobilization: comparative studies in a murine model.
Verma UN; van den Blink B; Pillai R; Chawla J; Mazumder A; Herscowitz HB; Meehan KR
Exp Hematol; 1999 Mar; 27(3):553-60. PubMed ID: 10089919
[TBL] [Abstract][Full Text] [Related]
38. Stimulation of suppressor cells in the bone marrow and spleens of high dose cyclophosphamide-treated C57Bl/6 mice.
Nikcevich DA; Duffie GP; Young MR; Ellis NK; Kaufman GE; Wepsic HT
Cell Immunol; 1987 Oct; 109(2):349-59. PubMed ID: 2959374
[TBL] [Abstract][Full Text] [Related]
39. Generation of specific antitumor cytotoxic T-lymphocytes in monoculture can be inhibited by T-suppressors from tumor-bearing mice.
Lupatov AYu ; Brondz BD
Cancer Biother; 1994; 9(2):123-9. PubMed ID: 7812361
[TBL] [Abstract][Full Text] [Related]
40. Regulation of T- and B lymphocyte responses to mitogens by tumor-associated macrophages: the dependency on the stage of tumor growth.
Evans R
J Leukoc Biol; 1984 Jun; 35(6):549-59. PubMed ID: 6610014
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
